Alex

Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome

Press Release / By

– Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome – BASEL, Switzerland, Oct. 30, 2024 – Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study evaluating the safety and efficacy of gemlapodect (NOE-105) in Tourette syndrome. […]

Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome Read More »

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints

Press Release / By

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the target clinical dose range were responders based on the primary efficacy assessment The Yale Global Tics Severity Scale Total Tic Score (YGTSS-TTS) showed a statistically significant improvement of -7.8 points

Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints Read More »

Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause

Press Release / By

NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 – Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been dosed in a Phase 2a open-label

Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause Read More »

Noema Pharma to Present at Two Upcoming Conferences

Press Release / By

BASEL, Switzerland, January 3, 2024 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of management will attend and present at two upcoming conferences in San Francisco, CA. SACHS 7th Annual Neuroscience Innovation ForumFormat: Panel Discussion Title: Exploring New Modalities for Rare & Orphan Neurological Diseases

Noema Pharma to Present at Two Upcoming Conferences Read More »